Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 2
LXEO · 52886X107
|
8.4% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 8.4% | ||||
| Michael Cho | 8.4% | ||||
|
Equillium Inc.
13G
EQ · 29446K106
|
6.5% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 6.5% | ||||
| Michael Cho | 6.5% | ||||
|
Amanat Acquisition Corp.
13G
AMAN · G0375M101
|
5.0% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 5.0% | ||||
| Michael Cho | 5.0% | ||||
|
First Tracks Biotherapeutics, Inc
13G
TRAX · 337185102
|
5.8% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 5.8% | ||||
| Michael Cho | 5.8% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 3
FBRX · 34962G208
|
5.6% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 5.6% | ||||
| Michael Cho | 5.6% | ||||
|
Ovid Therapeutics Inc.
13G/A
Amendment 3
OVID · 690469101
|
7.9% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 7.9% | ||||
| Michael Cho | 7.9% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 4
AVTX · 05338F306
|
5.5% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 5.5% | ||||
| Michael Cho | 5.5% | ||||
|
iBio, Inc.
13G/A
Amendment 4
IBIO · 451033708
|
10.0% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 10.0% | ||||
| Michael Cho | 10.0% | ||||
|
NextCure, Inc.
13G/A
Amendment 4
NXTC · 65343E207
|
6.4% |
8/13/2026
Event 6/30/2026
|
|||
| Affinity Asset Advisors, LLC | 6.4% | ||||
| Michael Cho | 6.4% | ||||
|
Ovid Therapeutics Inc.
13G/A
Amendment 2
OVID · 690469101
|
9.1% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 9.1% | ||||
| Michael Cho | 9.1% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 2
FBRX · 34962G208
|
7.3% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 7.3% | ||||
| Michael Cho | 7.3% | ||||
|
Ventyx Bioscience, Inc.
13G/A
Amendment 2
VTYX · 92332V107
|
0% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 0% | ||||
| Michael Cho | 0% | ||||
|
Sutro Biopharma, Inc.
13G/A
Amendment 2
STRO · 869367201
|
6.5% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 6.5% | ||||
| Michael Cho | 6.5% | ||||
|
iBio, Inc.
13G/A
Amendment 3
IBIO · 451033708
|
10.0% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 10.0% | ||||
| Michael Cho | 10.0% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 3
AVTX · 05338F306
|
5.5% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 5.5% | ||||
| Michael Cho | 5.5% | ||||
|
Helix Acquisition Corp. III
13G
HLXC · G4444S107
|
7.0% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 7.0% | ||||
| Michael Cho | 7.0% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
Amendment 2
KPTI · 48576U205
|
8.6% |
5/14/2026
Event 3/31/2026
|
|||
| Affinity Asset Advisors, LLC | 8.6% | ||||
| Michael Cho | 8.6% | ||||
|
NextCure, Inc.
13G/A
Amendment 3
NXTC · 65343E207
|
10.0% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 10.0% | ||||
| Michael Cho | 10.0% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
Amendment 1
KPTI · 48576U205
|
8.6% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 8.6% | ||||
| Michael Cho | 8.6% | ||||
|
iBio, Inc.
13G/A
Amendment 2
IBIO · 451033708
|
10.0% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 10.0% | ||||
| Michael Cho | 10.0% | ||||
|
Ventyx Bioscience, Inc.
13G/A
Amendment 1
VTYX · 92332V107
|
9.0% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 9.0% | ||||
| Michael Cho | 9.0% | ||||
|
Verrica Pharmaceuticals Inc.
13G/A
Amendment 1
VRCA · 92511W207
|
5.5% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 5.5% | ||||
| Michael Cho | 5.5% | ||||
|
Lexeo Therapeutics, Inc.
13G/A
Amendment 1
LXEO · 52886X107
|
7.1% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 7.1% | ||||
| Michael Cho | 7.1% | ||||
|
Sutro Biopharma, Inc.
13G/A
Amendment 1
STRO · 869367201
|
8.8% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 8.8% | ||||
| Michael Cho | 8.8% | ||||
|
Forte Biosciences, Inc.
13G/A
Amendment 1
FBRX · 34962G208
|
6.7% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 6.7% | ||||
| Michael Cho | 6.7% | ||||
|
Ovid Therapeutics Inc.
13G/A
Amendment 1
OVID · 690469101
|
9.0% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 9.0% | ||||
| Michael Cho | 9.0% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 2
AVTX · 05338F306
|
5.7% |
1/29/2026
Event 1/22/2026
|
|||
| Affinity Asset Advisors, LLC | 5.7% | ||||
| Michael Cho | 5.7% | ||||
|
Forte Biosciences, Inc.
13G
FBRX · 34962G208
|
6.9% |
12/23/2025
Event 12/17/2025
|
|||
| Affinity Asset Advisors, LLC | 6.9% | ||||
| Affinity Healthcare Fund, LP | 6.9% | ||||
|
Ovid Therapeutics Inc.
13G
OVID · 690469101
|
9.0% |
12/18/2025
Event 12/11/2025
|
|||
| Affinity Asset Advisors, LLC | 9.0% | ||||
| Affinity Healthcare Fund, LP | 9.0% | ||||
|
Verrica Pharmaceuticals Inc.
13G
VRCA · 92511W207
|
5.5% |
12/3/2025
Event 11/25/2025
|
|||
| Affinity Asset Advisors, LLC | 5.5% | ||||
| Affinity Healthcare Fund, LP | 5.5% | ||||
|
iBio, Inc.
13G/A
Amendment 1
IBIO · 451033708
|
10.0% |
12/3/2025
Event 8/19/2025
|
|||
| Affinity Asset Advisors, LLC | 10.0% | ||||
| Affinity Healthcare Fund, LP | 10.0% | ||||
|
NextCure, Inc.
13G/A
Amendment 2
NXTC · 65343E207
|
7.2% |
11/14/2025
Event 9/30/2025
|
|||
| Affinity Healthcare Fund, LP | 7.2% | ||||
| Affinity Asset Advisors, LLC | 7.2% | ||||
|
Avalo Therapeutics, Inc.
13G/A
Amendment 1
AVTX · 05338F306
|
7.7% |
11/13/2025
Event 9/30/2025
|
|||
| Affinity Healthcare Fund, LP | 7.7% | ||||
| Affinity Asset Advisors, LLC | 7.7% | ||||
|
Sutro Biopharma, Inc.
13G
STRO · 869367102
|
7.8% |
10/23/2025
Event 10/16/2025
|
|||
| Affinity Healthcare Fund, LP | 7.8% | ||||
| Affinity Asset Advisors, LLC | 7.8% | ||||
|
iBio, Inc.
13G
IBIO · 451033708
|
10.0% |
8/26/2025
Event 8/19/2025
|
|||
| Affinity Healthcare Fund, LP | 10.0% | ||||
| Affinity Asset Advisors, LLC | 10.0% | ||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
7.8% |
6/4/2025
Event 5/28/2025
|
|||
| Affinity Healthcare Fund, LP | 7.8% | ||||
| Affinity Asset Advisors, LLC | 7.8% | ||||
|
Ventyx Biosciences, Inc.
13G
VTYX · 92332V107
|
5.7% |
5/30/2025
Event 5/22/2025
|
|||
| Affinity Healthcare Fund, LP | 5.7% | ||||
| Affinity Asset Advisors, LLC | 5.7% | ||||
|
Inozyme Pharma, Inc.
13G/A
Amendment 1
INZY · 45790W108
|
2.9% |
5/30/2025
Event 5/20/2025
|
|||
| Affinity Healthcare Fund, LP | 2.9% | ||||
| Affinity Asset Advisors, LLC | 2.9% | ||||
|
Karyopharm Therapeutics Inc.
13G
KPTI · 48576U205
|
7.8% |
4/10/2025
Event 4/3/2025
|
|||
| Affinity Healthcare Fund, LP | 7.8% | ||||
| Affinity Asset Advisors, LLC | 7.8% | ||||
|
Avalo Therapeutics, Inc.
13G
AVTX · 05338F306
|
5.3% |
12/31/2024
Event 12/23/2024
|
|||
| Affinity Healthcare Fund, LP | 5.3% | ||||
| Affinity Asset Advisors, LLC | 5.3% | ||||